Datapoint: GSK Scores Nasal Polyps Approval for Nucala

The FDA on July 29 approved GlaxoSmithKline’s Nucala for the treatment of chronic rhinosinusitis with nasal polyps, making it the first IL-5 inhibitor in its class. The biologic will have to face off against Sanofi and Regeneron’s Dupixent, which was approved for nasal polyps in 2019. Under the pharmacy benefit, Dupixent holds preferred status (with utilization management restrictions applied in most cases) for 38% of all covered lives. Overall, it holds covered or better status for 73% of lives.

SOURCE: MMIT Analytics, as of 8/2/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 8

Datapoint: Aetna-Allina Health Launch New Plan Designs in Minnesota

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 7

Datapoint: Oklahoma Medicaid Rolls Top 1M After Expansion

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 6

Datapoint: Blue Cross and Blue Shield of Montana Plots Medicare Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today